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sidered all patients undergoing elective, urgent, or emergent PCI
at Mayo Clinic Rochester between 3/1/1998–3/31/2003 in analy-
ses. Clinical, angiographic, and outcome data were derived from
the Mayo Clinic PCI Registry. In-hospital PCI complications
included major adverse cardiac and cerebrovascular events
(MACCE) (deﬁned as death, myocardial infarction [MI], emer-
gent coronary bypass surgery, repeat PCI, or stroke) and bleed-
ing of clinical signiﬁcance. Administrative data was used to
estimate total costs (hospital and physician) in standardized, year
2004 constant-dollars. We used generalized linear modeling to
estimate the incremental costs associated with complications
adjusting for demographic, clinical, angiographic, and proce-
dural characteristics. RESULTS: 1071 (13.2%) of patients 
experienced at least one of the selected complications during hos-
pitalization. Patients experiencing complications were older,
more likely to present with emergent PCI, recent or prior MI,
multi-vessel disease, B2/C type lesions, and comorbid conditions
than patients who did not experience these events. Unadjusted
total costs were, on average, $27,865 ± $39,424 for patients who
experienced any complication compared to $12,279 ± $6796 for
those who were free of complications (p < 0.0001). Adjusted
mean total costs were $7000 higher for patients experiencing
complications compared with patients who were complication
free (95% CI of cost difference: $5,854, $8,145). Incremental
costs associated with only bleeding events, only MACCE, or 
for patients experiencing bleeding and MACCE events were
$5813, $5151, and $15,699, respectively (p < 0.0001). CON-
CLUSIONS: This observational study highlights the signiﬁcant
economic burden associated with in-hospital procedural compli-
cations. Interventions to reduce the risk of adverse events likely
enhance ﬁnancial as well as clinical performance.
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OBJECTIVE: The prevalence of VTE and its associated mor-
bidity and mortality is difﬁcult to assess. This is due to its often
silent nature, difﬁculty of diagnosis and follow up, and lack of
routine post-mortems. This is thought to result in marked under-
estimates of its true burden. VITA is the ﬁrst large-scale study
that aims to determine the burden of VTE at a European level.
METHODS: A modiﬁed incidence-based epidemiological model
was developed to estimate the number of VTE events and deaths
taking into consideration recurrence and complications. Separate
models were constructed for France, UK, Germany, Italy, Sweden
and Spain; the total number VTE events were extrapolated for
the EU. These comprehensive models were populated with pub-
lished literature when available and expert observation when
necessary. Both community-acquired and hospital-acquired
events were derived. The former were based on a large European
epidemiological study (EPI-GETBO) and the latter were derived
using a hospital episode statistics database in conjunction with
a “bottom-up” approach. RESULTS: The total annual burden
of VTE across the EU was estimated to be 641,275 symptomatic
deep-vein thromboses (DVT), and 382,550 pulmonary emboli
(PE). VTE-related deaths were estimated at 478,500. Of these
deaths, 34,450 (7%) patients had been diagnosed with VTE and
treated, 163,050 (34%) were estimated to be sudden fatal PE
and 281,000 (59%) followed undetected PE. These ﬁndings were
tested using probabilistic sensitivity analyses. CONCLUSIONS:
The VITAE study conﬁrms that VTE is a major public health
problem in the EU. Many of these events and deaths were sudden
or due to undetected disease. Given the availability of effective
VTE prophylaxis, many of these events and deaths are pre-
ventable. This is of particular importance in the medical setting
where the implementation of prophylaxis remains suboptimal.
Further research to estimate the impact of increased prophylaxis
use is urgently needed.
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OBJECTIVE: There are limited data documenting common
strategies used for inpatient thromboprophylaxis or describing
the costs associated with common treatment modalities. The aim
of the study was to assess treatment patterns, utilization of health
care resources and hospital costs associated with thrombopro-
phylaxis in real-world clinical practice in Poland. METHODS:
Data from inpatient records were collected prospectively for
patients hospitalized in 25 departments between 31.04.2004 and
31.05.2005. Stratiﬁed analyses were performed by baseline risk
of thrombosis and means of total cost for each group were cal-
culated, using participating hospitals account systems. Costs
comparisons related to risk groups were performed using non-
parametric tests with signiﬁcance level of 0.05. RESULTS: The
database contains information about 5348 patients. Of these
35% were general surgery, 23% medical, 15.3% vascular and
13% orthopedic surgery patients. 59% of patients were at
highest risk of VTE (I), 24% at high (II), 10% at moderate (III)
and 7% at low risk (IV). Thromboprophylaxis received 84%,
77%, 71% and 60% patients in I, II, III, and IV group, respec-
tively. Most admissions (76,%) involved LMHHs treatments,
administered for mean 10.2, 6.3, 6.0 and 5.8 days in group
I,II,III and IV respectively. Adverse events related to thrombo-
prophylaxis occurred in 2% of patients; 85% of these were
minor hemorrhages, 9% major hemorrhages, 2% thrombocy-
topenia. Post-discharge thromboprophylaxis was indicated for
34.6% patients, most frequently in patients after orthopedic
surgery (81.3%), trauma (66.3%) or cardiological hospitaliza-
tions (49%). The most common regimen in extended thrombo-
prophylaxis was LMWHs (77%). Mean cost of
thromboprophylaxis was 999 (+/-5964) PLN in I, 327 (+/-1598)
PLN in II, 260 (+/-695) PLN in III and 232 (+/-842) PLN in
group IV (1 EURO = 4 PLN, 2005) (p = 0.0001). CONCLU-
SION: Results from this study indicate that inpatient thrombo-
prophylaxis is in line with clinical guidelines. The risk
stratiﬁcation of hospitalized patients allows for the estimation of
costs.
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OBJECTIVES: Patients undergoing major orthopaedic proce-
dures such as hip fracture surgery (HFS) and total hip replace-
ment (THR) are at increased risk of developing venous
thromboembolic events (VTE). It was shown in the Penthifra
plus trial that extending fondaparinux prophylaxis from 1 week
to 4 weeks reduces the risk of VTE by 96%. Whether prolonged
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prophylaxis with fondaparinux is cost-effective was addressed in
this study. METHODS: A decision analytic model was developed
to compare a four-week fondaparinux regimen with a one-week
regimen. Clinical input parameters were derived from clinical
trials and other published sources. Cost data for Swiss univer-
sity hospitals were obtained from the single service tariffs data-
base (Tarmed), the Swiss Drugs Compendium and the diagnosis
related groups database (AP-DRG) and were expressed in 2004
Swiss francs (CHF). The model simulates a cohort of HFS and
THR patients over 30 days and 5 years. Outcomes were mea-
sured in life-years gained (LYG). Future costs and outcomes were
discounted with an annual rate of four percent. RESULTS: In a
hypothetical cohort of 1000 HFS patients, extended prophylaxis
avoids 10 fatal events and 9 VTEs over a time horizon of 30
days. The corresponding ICER is CHF 2801 per LYG. With a
lower baseline risk for VTE in THR patients, extended fonda-
parinux prophylaxis prevents one fatal event in 1000 patients
over a time horizon of 30 days, yielding an ICER of CHF20,294
per LYG. After ﬁve years, extended prophylaxis is cost saving in
both HFS and THR patients. The model results were robust to
variations of major clinical and cost parameters. CONCLU-
SIONS: Extended prophylaxis with fondaparinux in THR and
HFS patients is cost-effective from a Swiss health care perspec-
tive using a time horizon of 30 days. With a longer time horizon
of ﬁve years, extended prophylaxis with fondaparinux is 
cost-saving.
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OBJECTIVE: To determine the cost-effectiveness of fonda-
parinux compared with enoxaparin for extended prophylaxis
against venous thromboembolism in patients undergoing hip
fracture surgery using Dutch estimates of costs. METHODS:
Costs and effects are modeled using a cohort simulation model.
Short term transition probabilities (until day 30) are based from
placebo controlled trials. Long term probabilities are obtained
from the literature. Resource use and costs were obtained from
a Dutch costing study concerning bleedings and symptomatic
events. Outcome measures were rates of symptomatic throm-
boembolic events, deaths avoided and health care costs. Costs
were in 2003 values. “Conﬁdence intervals” (CI) are obtained
by probabilistic sensitivity analysis. RESULTS: Fondaparinux
was estimated to prevent an additional 158 symptomatic venous
thromboembolic events (per 10,000 patients) at 1 year after
major orthopaedic surgery compared with enoxaparin (95%
CI:163–371). The cost savings (per patient) of using fonda-
parinux over enoxaparin are estimated at €103 (€34–€178). The
number of deaths avoided (per 10,000 patients) is estimated at
103 (57–165). The probability that fondaparinux is both more
effective and cost saving is estimated at 0.9996. CONCLUSION:
Extended prophylaxis with fondaparinux after major orthope-
dic surgery can be expected to result in both better outcomes and
cost savings when compared with extended prophylaxis with
enoxaparin.
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OBJECTIVE: To determine the cost effectiveness of extended
prophylaxis with fondaparinux to prevent venous thromboem-
bolism in patients undergoing hip fracture surgery compared to
short term using UK and Dutch estimates of costs. METHODS:
Costs and effects are modeled using a cohort simulation model.
Short term transition probabilities (until day 30) are obtained
from placebo controlled trials. Long term probabilities are
obtained from the literature. UK resource use and costs were
obtained from a published analysis concerning short term 
prophylaxis. Dutch resource use and costs were estimated in a
separate costing study concerning bleedings and symptomatic
events. Outcome measures were rates of symptomatic throm-
boembolic events, deaths avoided and health care costs. Costs
were in 2004 values. “Conﬁdence intervals” (CI) were obtained
by probabilistic sensitivity analysis. RESULTS: At one year
extending prophylaxis with fondaparinux after major
orthopaedic surgery from 7 to 22 days was estimated to prevent
343 symptomatic venous thromboembolic events (per 10,000
patients) (95% CI:283–391). The additional cost (per patient) of
extending the prophylactic period is estimated at £164
(£117–£212) in the UK and at €66 in The Netherlands. The
number of deaths avoided (per 10,000 patients) is estimated at
138 (89–192). Costs per symptomatic VTE avoided are esti-
mated at £4,788 (£3258–£6906) in the UK and at €1915
(€392–€4021) in The Netherlands. Costs per death avoided 
are estimated at £11,932 (£7220–£20,480) and €4773
(€892–€11,629). When assuming the average survival after
surgery at 6 years, costs per life year gained are estimated at
under £3,000 for the UK and at under €900 for The Nether-
lands. CONCLUSION: Our estimates indicate that extending
the prophylaxis with fondaparinux from 7 to 21 days has an
acceptable balance between cost and outcomes both in the UK
and The Netherlands.
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Oral anticoagulation is indicated for a number of conditions,
including prevention of systemic embolism in patients with
mechanical heart valves, valvular heart disease, myocardial
infarction and atrial ﬁbrillation. VKA are frequently prescribed
as long term treatment. Due to the features of treatment, VKA
have the potential to cause dissatisfaction and reduce QoL.
OBJECTIVES: To assess Health- Related Quality of life
(HRQOL) in patients receiving VKA comparing their health
status with matched controls. METHODS. Ninety-two consec-
utive patients receiving VKA (53 male; age range 37–81 years)
were enrolled among those followed by our anticoagulation
clinic. The more frequent indications for VKA treatment were
atrial ﬁbrillation and venous thromboembolism. Each patient
was matched by age and sex with one control from a database
of a population based naturalistic prospective survey. The
EuroQoL, completed during the enrolment visit, was used to
evaluate HRQOL. To evaluate differences in the ﬁve dimensions
